RT Book, Section
A1 CHU, VALERY L.
A1 MALTZ, HELENE C.
A2 Cohen, Henry
SR Print(0)
ID 1112259866
T1 Warfarin
T2 Casebook in Clinical Pharmacokinetics and Drug Dosing
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 9780071628358
LK accesspharmacy.mhmedical.com/content.aspx?aid=1112259866
RD 2024/04/25
AB Following  the  isolation  of  hemorrhagic  agents  from  spoiled  sweet  clover  hay  in  the  1930s  and  development  of  3-phenyacetyl  ethyl,  4-hydroxycoumarin  as  a  rat  poison  in  1948,  warfarin  has  been  the  primary  oral  anticoagulant  used  in  North  America  since  its  approval  for  medical  use  in  1954.1  Even  following  the  availability  of  new  oral  anticoagulant  classes,  it  is  widely  used  for  its  various  indications  including  prophylaxis  and  treatment  of  venous  thrombosis  and  pulmonary  embolism,  prophylaxis  and  treatment  of  thromboembolic  complications  of  atrial  fibrillation  and  heart  valve  replacement,  and  postmyocardial  infarction  (MI)  reduction  in  the  risk  of  death,  recurrent  MI,  and  thromboembolic  events  such  as  stroke  or  systemic  embolization.2